Search
Norelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigationalNorelgestromin was first approved in the United States in 2001 as the progestin in a norelgestromin and ethinyl estradiol transdermal contraceptive system.[L63816] … It is administered transdermally in combination with the estrogen [ethinyl estradiol], delivering both hormones systemically over a 7-day wear period.
Necitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnNecitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). … Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist.
Ibandronate
go.drugbank.com/drugs/DB00710ApprovedInvestigational[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805]
Products: ACIDO IBANDRONICO EG, BONVIVA 3MG/3ML ILO IN FEREplerenone
go.drugbank.com/drugs/DB00700ApprovedInvestigationalEplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors. … regulatory feedback of aldosterone on renin secretion.
Dinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalneuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. … Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse.
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently
Steroidogenesis
smpdb.ca/view/SMP0000130MetabolicThe enzyme CYP21A2 then hydroxylates progesterone, which converts it to deoxycorticosterone. … Some of these desired steroids include cortisol, corticoids, testosterone, estrogens, aldosterone and progesterone.
17-alpha-Hydroxylase Deficiency (CYP17)
smpdb.ca/view/SMP0000566DiseaseWhen mutated, it leads to an accumulation of pregnenolone, progesterone, deoxycorticosterone and 11-dehydrocorticosterone throughout the cell. 17-alpha hydroxylase deficiency is characterized by a deficiency … This enzyme hydroxylates both progesterone and pregnenolone into 17-hydroxyprogesterone and 17a-hydroxypregnenolone respectively in the mitochondria, as well as hydroxylating 21-deoxycortisol to 11b-hydroxyprogesterone
3-beta-Hydroxysteroid Dehydrogenase Deficiency
smpdb.ca/view/SMP0000718Disease3-beta-hydroxysteroid dehydrogenase (HSD) deficiency is an extremely rare inborn error of metabolism (IEM) and autosomal recessive disorder of the steroidogenesis pathway. It is caused by an defect in the HSD3B2 gene which encodes for th...
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
smpdb.ca/view/SMP0125797DiseaseIt also catalyzes hydroxylation of progesterone to 11-deoxycorticosterone (DOC) in the mineralocorticoid pathway on its way from pregnenolone to aldosterone. … A defect in this enzyme results in accumulation of 17-Hydroxyprogesterone, progesterone and 17a-Hydroxypregnenolone, androstenedione, and testosterone; decreased levels of cortexolone, deoxycorticosterone